Distinct demographic, systemic sclerosis-specific, and cardiac factors are linked to a higher risk for left ventricular ...

Objective The left atrial stiffness index (LASI) has been proven to be a promising marker for assessing left atrial (LA) and ...

Background Fabry disease (FD) is an X linked lysosomal disorder with ventricular myocardial involvement that drives morbidity and mortality. Early diagnosis of cardiac involvement can be difficult.

NEW ORLEANS -- A polypill that combines three of the four mainstays of treatment for heart failure with reduced ejection ...

Among patients with heart failure and reduced ejection fraction (HFrEF), those taking a “polypill” combination of three medications typically prescribed for heart failure, once daily for six months, ...

A once-daily polypill containing 3 guideline-directed therapies for heart failure with reduced ejection fraction (HFrEF) led ...

TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced ...

Adults with heart failure with reduced ejection fraction (HFrEF) who took a "polypill" combining medications prescribed for the treatment of heart failure, had improved heart function and symptoms, ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to have dosed 30 ...

Michael Gotthardt at the Max Delbrück Center and collaborators are developing a drug to treat a common type of heart failure characterized by impaired cardiac filling. In “Cardiovascular Research,” ...